Hereditary dementia
MONDO:0015547An instance of dementia that is caused by an inherited genomic modification in an individual.
Also known as: genetic dementia
322 clinical trials for this condition and its sub-types, 2 tagged with Hereditary dementia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hereditary dementia
-
Frontotemporal dementia 132 trials · 178 incl. sub-types
4 sub-types
- GRN-related frontotemporal lobar degeneration with Tdp43 inclusions 6 trials · 47 incl. sub-types Sub-types →
- Behavioral variant of frontotemporal dementia 21 trials · 42 incl. sub-types Sub-types →
- Pick disease 35 trials
- Inclusion body myopathy with Paget disease of bone and frontotemporal dementia 1 trial · 3 incl. sub-types Sub-types →
-
Familial Alzheimer disease 13 trials · 55 incl. sub-types
2 sub-types
- Early-onset autosomal dominant Alzheimer disease 31 trials · 37 incl. sub-types Sub-types →
- Alzheimer disease 2 11 trials
-
Autosomal dominant cerebellar ataxia 11 trials · 33 incl. sub-types
15 sub-types
- Autosomal dominant cerebellar ataxia type I 0 trials · 16 incl. sub-types Sub-types →
- Autosomal dominant cerebellar ataxia type III 0 trials · 9 incl. sub-types Sub-types →
- Autosomal dominant cerebellar ataxia type IV 0 trials · 8 incl. sub-types Sub-types →
- Spinocerebellar ataxia 7 7 trials
- Spinocerebellar ataxia 27B, late-onset 4 trials
- Spinocerebellar ataxia 9 2 trials
- Spinocerebellar ataxia 27A 1 trial
- GRID2-related autosomal dominant spinocerebellar ataxia 0 trials
- Spinocerebellar ataxia 43 0 trials
- Spinocerebellar ataxia 44 0 trials
- Spinocerebellar ataxia 47 0 trials
- Spinocerebellar ataxia 48 0 trials
- Spinocerebellar ataxia 49 0 trials
- Spinocerebellar ataxia 50 0 trials
- Spinocerebellar ataxia 51 0 trials
-
Metachromatic leukodystrophy 20 trials
2 sub-types
- Metachromatic leukodystrophy, juvenile form 2 trials · 4 incl. sub-types Sub-types →
- Metachromatic leukodystrophy due to saposin B deficiency 0 trials
-
Adrenoleukodystrophy 19 trials · 20 incl. sub-types
3 sub-types
- Adrenomyeloneuropathy 7 trials
- X-linked cerebral adrenoleukodystrophy 4 trials
- Isolated adrenal insufficiency 0 trials
-
Corticobasal syndrome 19 trials
-
Frontotemporal dementia with motor neuron disease 13 trials · 19 incl. sub-types
7 sub-types
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 5 trials
- Amyotrophic lateral sclerosis type 10 3 trials
- Amyotrophic lateral sclerosis type 6 1 trial
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 0 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 0 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 0 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 6 0 trials
-
Huntington disease-like syndrome 0 trials · 17 incl. sub-types
10 sub-types
- Machado-Joseph disease 11 trials Sub-types →
- Spinocerebellar ataxia type 1 10 trials
- Spinocerebellar ataxia type 2 10 trials Sub-types →
- Dentatorubral-pallidoluysian atrophy 4 trials
- Huntington disease-like 3 0 trials
- Huntington disease-like syndrome due to C9ORF72 expansions 0 trials
- Childhood-onset benign chorea with striatal involvement 0 trials
- Neuroacanthocytosis 0 trials Sub-types →
- Neuroferritinopathy 0 trials
- Spinocerebellar ataxia type 17 0 trials
-
Posterior cortical atrophy 11 trials
-
Neurodegeneration with brain iron accumulation 1 trial · 8 incl. sub-types
14 sub-types
- Neurodegeneration with brain iron accumulation 5 4 trials
- Pantothenate kinase-associated neurodegeneration 4 trials Sub-types →
- PLA2G6-associated neurodegeneration 1 trial Sub-types →
- Kufor-Rakeb syndrome 0 trials Sub-types →
- Woodhouse-Sakati syndrome 0 trials
- Aceruloplasminemia 0 trials
- Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome 0 trials
- Fatty acid hydroxylase-associated neurodegeneration 0 trials
- Neurodegeneration with brain iron accumulation 4 0 trials
- Neurodegeneration with brain iron accumulation 6 0 trials
- Neurodegeneration with brain iron accumulation 7 0 trials
- Neurodegeneration with brain iron accumulation 8 0 trials
- Neurodegeneration with brain iron accumulation 9 0 trials
- Neuroferritinopathy 0 trials
-
Alzheimer disease 17 1 trial
-
Alzheimer disease 18 1 trial
Most studied deeper sub-types
-
Spinal injection drug targets genetic cause of ALS and dementia
Disease control Stopped earlyResearchers are testing repeated doses of an experimental drug called WVE-004 in adults who have ALS, frontotemporal dementia, or both, linked to a mutation in the C9orf72 gene. Participants receive the drug by spinal injection every 12 weeks for up to 96 weeks. The study tracks …
Phase 1/2 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Halted gene therapy study raises questions for AMN patients
Disease control Stopped earlyThis early-stage trial tested a gene therapy called SBT101 for adrenomyeloneuropathy (AMN), a rare nerve disease that causes walking difficulties. Eight adults received either the therapy or a sham procedure. The study was terminated early, so we have limited data on safety and e…
Phase 1/2 • Sponsor: SwanBio Therapeutics, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Neurodegenerative drug study ends early after only 17 participants
Disease control Stopped earlyThis study was designed to let people who had already taken latozinemab in an earlier study continue receiving the drug. Only 17 people took part, and the study was stopped early. The goal was to track safety and how long people stayed on treatment, not to test if the drug could …
Phase 3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Hope for genetic dementia: AL001 trial ends early
Disease control Stopped earlyThis phase 3 study tested a drug called AL001 in 119 people who carry a mutation in the progranulin gene, putting them at high risk for or already diagnosed with frontotemporal dementia. The goal was to see if AL001 could slow the worsening of memory, behavior, and language probl…
Phase 3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could a High-Fat diet boost brain health in early Alzheimer's?
Symptom relief Stopped earlyThis study looks at whether a ketogenic diet (high-fat, low-carb) is practical and safe for people with early-stage Alzheimer's disease over one year. The diet may provide an alternative energy source for the brain and reduce inflammation. Researchers will track diet adherence, b…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Dementia agitation drug trial halted after just 5 patients
Symptom relief Stopped earlyThis study tested a fast-dissolving film (BXCL501) placed under the tongue to quickly reduce severe agitation in older adults with dementia. The trial aimed to enroll many participants but was stopped early after only 5 people joined. Because it ended so soon, we cannot draw reli…
Phase 2 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a synthetic cannabinoid calm agitation in frontotemporal dementia?
Symptom relief Stopped earlyThis phase 2 trial tests whether nabilone, a synthetic cannabinoid, can reduce agitation in people with frontotemporal dementia (FTD). Participants receive both nabilone and a placebo in random order to compare effects. The study includes adults with behavioral variant FTD or pri…
Phase 2 • Sponsor: Simon Ducharme, MD • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Experimental drug aims to curb disinhibition in dementia patients
Symptom relief Stopped earlyThis study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated ear…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Touchscreen device aims to give voice to dementia patients
Symptom relief Stopped earlyThis study tested a personalized touchscreen device (My PATI) to help people with Alzheimer's or related dementias communicate their care preferences. The goal was to improve quality of life for both patients and their caregivers. The study was terminated early, so results are li…
Sponsor: Florida International University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New drug aimed at treating apathy in dementia patients tested
Symptom relief Stopped earlyThis study tested a drug called CVL-871 to see if it is safe and can help reduce apathy (lack of motivation or interest) in people with dementia. The trial included 41 participants with mild to moderate dementia and clinically significant apathy. The main goal was to check for si…
Phase 2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Could a Head-Zap at home boost your brain?
Symptom relief Stopped earlyThis study tested whether a gentle, non-invasive brain stimulation technique (tDCS) done at home, along with computer-based brain games, could improve thinking and language skills in people with primary progressive aphasia, mild cognitive impairment, or dementia. Participants use…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Brain scans reveal why dementia changes personality
Knowledge-focused Stopped earlyThis study investigates how Alzheimer's disease and frontotemporal dementia alter a person's sense of self and ability to understand others. Researchers will compare patients with healthy older adults using questionnaires and brain imaging. The goal is to link changes in self-awa…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Rare disease mystery: scientists watch AMN progress in hopes of finding a cure
Knowledge-focused Stopped earlyThis study followed 65 adult men with a rare inherited nerve disease called AMN (a form of spastic paraplegia) to understand how their symptoms change over time. Researchers collected data on walking ability and quality of life. The goal was to fill gaps in knowledge about the di…
Sponsor: SwanBio Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC